Allogene Therapeutics (ALLO) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $1.31, -2.24% vs the prior close of $1.34.
- Volume 4.92M shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ALLO dips 2.2% to $1.31. Closed at $1.31, -2.24% vs the prior close of $1.34. Day range $1.29–$1.34, opened at $1.34.
ALLO daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — ALLO dips 2.2% to $1.31
- Closed at $1.31, -2.24% vs the prior close of $1.34. Day range $1.29–$1.34, opened at $1.34.
- Volume was 4.92M shares, 0.9x its 50-day average of 5.44M.
- Price is -26.4% vs its 50-day average ($1.78) and -34.3% vs its 200-day average ($1.99).
- 52-week range $1.04–$4.46; today's close sits at 8% of that range, 70.6% below the 52-week high.
Oct 15, 2026 — ALLO jumps 3.1% to $1.34
- Closed at $1.34, +3.08% vs the prior close of $1.30. Day range $1.30–$1.37, opened at $1.33.
- Volume was 4.51M shares, 0.8x its 50-day average of 5.45M.
- Price is -25.3% vs its 50-day average ($1.79) and -32.8% vs its 200-day average ($1.99).
- 52-week range $1.04–$4.46; today's close sits at 9% of that range, 70.0% below the 52-week high.
Oct 14, 2026 — ALLO rises 0.8% to $1.30
- Closed at $1.30, +0.78% vs the prior close of $1.29. Day range $1.22–$1.31, opened at $1.28.
- Volume was 7.74M shares, 1.4x its 50-day average of 5.40M.
- Price is -28.0% vs its 50-day average ($1.81) and -34.8% vs its 200-day average ($1.99).
- 52-week range $1.04–$4.46; today's close sits at 8% of that range, 70.9% below the 52-week high.
Oct 13, 2026 — ALLO slides 7.9% to $1.29, a 6-month low
- Closed at $1.29, -7.86% vs the prior close of $1.40. Day range $1.29–$1.40, opened at $1.39.
- Volume was 6.54M shares, 1.2x its 50-day average of 5.41M.
- Price is -29.1% vs its 50-day average ($1.82) and -35.3% vs its 200-day average ($1.99).
- 52-week range $1.04–$4.46; today's close sits at 7% of that range, 71.1% below the 52-week high.
Oct 12, 2026 — ALLO slides 4.1% to $1.40
- Closed at $1.40, -4.11% vs the prior close of $1.46. Day range $1.39–$1.46, opened at $1.45.
- Volume was 4.31M shares, 0.8x its 50-day average of 5.43M.
- Price is -23.5% vs its 50-day average ($1.83) and -29.8% vs its 200-day average ($1.99).
- 52-week range $1.04–$4.46; today's close sits at 11% of that range, 68.6% below the 52-week high.
Oct 9, 2026 — ALLO jumps 4.3% to $1.46 on 2.0x normal volume
- Closed at $1.46, +4.29% vs the prior close of $1.40. Day range $1.37–$1.48, opened at $1.39.
- Volume was 10.60M shares, 2.0x its 50-day average of 5.43M — unusually heavy trading.
- Price is -20.6% vs its 50-day average ($1.84) and -26.8% vs its 200-day average ($1.99).
- 52-week range $1.04–$4.46; today's close sits at 12% of that range, 67.3% below the 52-week high.
Oct 8, 2026 — ALLO dips 2.1% to $1.40, a 6-month low, 12 down days in a row
- Closed at $1.40, -2.10% vs the prior close of $1.43. Day range $1.35–$1.44, opened at $1.44.
- Volume was 7.98M shares, 1.4x its 50-day average of 5.52M.
- Price is -24.3% vs its 50-day average ($1.85) and -29.8% vs its 200-day average ($1.99).
- 52-week range $1.04–$4.46; today's close sits at 11% of that range, 68.6% below the 52-week high.
- That makes 12 straight losses.
Oct 7, 2026 — ALLO dips 2.1% to $1.43, a 6-month low, 11 down days in a row
- Closed at $1.43, -2.05% vs the prior close of $1.46. Day range $1.42–$1.47, opened at $1.46.
- Volume was 3.89M shares, 0.7x its 50-day average of 5.64M.
- Price is -23.0% vs its 50-day average ($1.86) and -28.3% vs its 200-day average ($1.99).
- 52-week range $1.04–$4.46; today's close sits at 11% of that range, 67.9% below the 52-week high.
- That makes 11 straight losses.
Oct 6, 2026 — ALLO dips 2.7% to $1.46, a 6-month low, 10 down days in a row
- Closed at $1.46, -2.67% vs the prior close of $1.50. Day range $1.43–$1.50, opened at $1.50.
- Volume was 4.65M shares, 0.8x its 50-day average of 5.69M.
- Price is -21.6% vs its 50-day average ($1.86) and -26.8% vs its 200-day average ($1.99).
- 52-week range $1.04–$4.46; today's close sits at 12% of that range, 67.3% below the 52-week high.
- That makes 10 straight losses.
Oct 5, 2026 — ALLO ends flat (+0.0%) to $1.50, 9 down days in a row
- Closed at $1.50, +0.00% vs the prior close of $1.50. Day range $1.45–$1.52, opened at $1.50.
- Volume was 4.44M shares, 0.8x its 50-day average of 5.69M.
- Price is -19.7% vs its 50-day average ($1.87) and -24.8% vs its 200-day average ($1.99).
- 52-week range $1.04–$4.46; today's close sits at 13% of that range, 66.4% below the 52-week high.
- That makes 9 straight losses.
Oct 2, 2026 — ALLO dips 2.6% to $1.50, a 6-month low, 8 down days in a row
- Closed at $1.50, -2.60% vs the prior close of $1.54. Day range $1.50–$1.58, opened at $1.57.
- Volume was 4.66M shares, 0.8x its 50-day average of 5.71M.
- Price is -19.9% vs its 50-day average ($1.87) and -24.8% vs its 200-day average ($1.99).
- 52-week range $1.04–$4.46; today's close sits at 13% of that range, 66.4% below the 52-week high.
- That makes 8 straight losses.
ALLO latest news & SEC filings
Every SEC filing by or about ALLO in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 30, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 2, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Aug 25, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Douglas Earl Martin sold 29,697 shares at $2.12 (≈$62.96K) on Aug 21, 2026
- Douglas Earl Martin sold 29,697 shares at $2.12 (≈$62.96K) on Aug 21, 2026
- Douglas Earl Martin sold 29,697 shares at $2.12 (≈$62.96K) on Aug 21, 2026
- Douglas Earl Martin sold 29,697 shares at $2.12 (≈$62.96K) on Aug 21, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 21, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 20, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form S-3 — Shelf registration (S-3)
Shelf registration (S-3) — lets the company sell securities over time
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 12, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $4.64M (prior year $0)
- Net income: -$42.68M (prior year -$50.94M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.13 (prior year -$0.23) (loss narrowed vs Jun 30, 2025)
Aug 12, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 7, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 7, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 6, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 23, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 23, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 23, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Things to know before you trade ALLO
- Last results release: Aug 12, 2026 (8-K Item 2.02). Previous ones: May 13, 2026, Mar 12, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 11, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.16% (largest 7.9%).
- Liquidity: about 5.75M shares (≈$7.53M) trade per day on average.
- 52-week position: $1.31 vs a range of $1.04–$4.46 (8% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Earl Martin Douglas sold 29,697 shares on Aug 21, 2026.
- Latest filings: 8-K Sep 2, 2026; 10-Q Aug 12, 2026; 8-K Aug 12, 2026.
- Share count: 345.49M shares outstanding (Aug 10, 2026), +55.7% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
ALLO market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 1.34 | 1.34 | 1.29 | 1.31 | 4.92M |
| Oct 15, 2026 | 1.33 | 1.37 | 1.30 | 1.34 | 4.51M |
| Oct 14, 2026 | 1.28 | 1.31 | 1.22 | 1.30 | 7.74M |
| Oct 13, 2026 | 1.39 | 1.40 | 1.29 | 1.29 | 6.54M |
| Oct 12, 2026 | 1.45 | 1.46 | 1.39 | 1.40 | 4.31M |
| Oct 9, 2026 | 1.39 | 1.48 | 1.37 | 1.46 | 10.60M |
| Oct 8, 2026 | 1.44 | 1.44 | 1.35 | 1.40 | 7.98M |
| Oct 7, 2026 | 1.46 | 1.47 | 1.42 | 1.43 | 3.89M |
| Oct 6, 2026 | 1.50 | 1.50 | 1.43 | 1.46 | 4.65M |
| Oct 5, 2026 | 1.50 | 1.52 | 1.45 | 1.50 | 4.44M |
| Oct 2, 2026 | 1.57 | 1.58 | 1.50 | 1.50 | 4.66M |
| Oct 1, 2026 | 1.60 | 1.61 | 1.53 | 1.54 | 4.61M |
| Sep 30, 2026 | 1.61 | 1.66 | 1.58 | 1.60 | 8.13M |
| Sep 29, 2026 | 1.60 | 1.65 | 1.60 | 1.62 | 4.32M |
| Sep 28, 2026 | 1.65 | 1.67 | 1.60 | 1.63 | 5.03M |
| Sep 25, 2026 | 1.69 | 1.70 | 1.63 | 1.65 | 3.62M |
| Sep 24, 2026 | 1.67 | 1.72 | 1.60 | 1.67 | 7.79M |
| Sep 23, 2026 | 1.73 | 1.74 | 1.65 | 1.67 | 5.97M |
| Sep 22, 2026 | 1.72 | 1.74 | 1.68 | 1.71 | 5.23M |
| Sep 21, 2026 | 1.71 | 1.72 | 1.65 | 1.69 | 5.99M |
About Allogene Therapeutics
Allogene Therapeutics (ALLO) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in SOUTH SAN FRANCISCO, CA. Fiscal year ends December 31. SEC CIK 1737287.
ALLO board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Elizabeth A. Barrett | Director | Jun 23, 2026 |
| Arie Belldegrun | Director | Feb 4, 2026 |
| David D Chang | President and CEO | Mar 18, 2026 |
| Franz B Humer | Director | Jun 23, 2026 |
| Joshua A Kazam | Director | Jun 23, 2026 |
| Deborah M. Messemer | Director | Jun 23, 2026 |
| Stephen Mayo | Director | Jun 23, 2026 |
| Vicki L Sato | Director | Jun 23, 2026 |
| Owen N. Witte | Director | Jun 23, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Benjamin Machinas Beneski | SVP, Chief Technical Officer | Apr 2, 2026 |
| David D Chang | President and CEO | Mar 18, 2026 |
| Earl Martin Douglas | SVP, General Counsel | Aug 25, 2026 |
| Geoffrey M. Parker | CHIEF FINANCIAL OFFICER | Feb 4, 2026 |
| Zachary Roberts | President and CEO | Jul 6, 2026 |
| Annie Yoshiyama | SVP, Finance | Apr 23, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 21, 2026 | Earl Martin Douglas | Sale | 29,697 | $2.12 |
| Aug 21, 2026 | Earl Martin Douglas | Sale | 29,697 | $2.12 |
| Aug 21, 2026 | Earl Martin Douglas | Sale | 29,697 | $2.12 |
| Aug 21, 2026 | Earl Martin Douglas | Sale | 29,697 | $2.12 |
| Apr 21, 2026 | Annie Yoshiyama | Sale | 9,586 | $2.31 |
| Apr 21, 2026 | Annie Yoshiyama | Sale | 9,586 | $2.31 |
| Apr 21, 2026 | Annie Yoshiyama | Sale | 9,586 | $2.31 |
| Apr 21, 2026 | Annie Yoshiyama | Sale | 9,586 | $2.31 |
| Mar 31, 2026 | Benjamin Machinas Beneski | Sale | 2,867 | $2.50 |
| Mar 31, 2026 | Benjamin Machinas Beneski | Sale | 2,867 | $2.50 |
| Mar 31, 2026 | Benjamin Machinas Beneski | Sale | 2,867 | $2.50 |
| Mar 31, 2026 | Benjamin Machinas Beneski | Sale | 2,867 | $2.50 |
| Mar 16, 2026 | Benjamin Machinas Beneski | Sale | 4,835 | $2.47 |
| Mar 16, 2026 | Benjamin Machinas Beneski | Sale | 4,835 | $2.47 |
| Mar 16, 2026 | Benjamin Machinas Beneski | Sale | 4,835 | $2.47 |
ALLO financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $0 | $-190.89M | -0.87 | $-149.25M |
| Dec 31, 2024 | $22.00K | $-257.59M | -1.32 | $-200.30M |
| Dec 31, 2023 | $95.00K | $-327.26M | -2.09 | $-237.73M |
| Dec 31, 2022 | $156.00K | $-340.41M | -2.38 | $-220.52M |
| Dec 31, 2021 | $114.09M | $-182.05M | -1.34 | $-184.81M |
Latest balance sheet: total assets $550.09M, total liabilities $113.92M, cash $38.63M (as of Jun 30, 2026).
ALLO earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 12, 2026 | 8-K Item 2.02 (results) | $2.07 |
| May 13, 2026 | 8-K Item 2.02 (results) | $2.33 |
| Mar 12, 2026 | 8-K Item 2.02 (results) | $2.47 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $1.05 |
| Aug 13, 2025 | 8-K Item 2.02 (results) | $1.04 |
| May 13, 2025 | 8-K Item 2.02 (results) | $1.13 |
| Mar 13, 2025 | 8-K Item 2.02 (results) | $1.89 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $3.19 |
| Aug 7, 2024 | 8-K Item 2.02 (results) | — |
| May 13, 2024 | 8-K Item 2.02 (results) | — |
| Mar 14, 2024 | 8-K Item 2.02 (results) | — |
| Nov 2, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on ALLO
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.